Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-HIV-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target HIV-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HIV-1 antibody linked to CD3ζ signaling domains. And the vector product was designed for the treatment of HIV-1 infection.
|
CAR Construction : 3BNC117-41BB-CD3ζ
Fig.1 CAR-T cells displayed preferable immunophenotype. The subset composition of UTD/3B/3BD CAR-T cells were measured by surface expression of CD45RA and CD62L. Jiang, Zhengtao, et al. "HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo." Frontiers in Microbiology 12 (2021): 684016. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3BNC117-41BB-CD3ζ
Fig.2 CAR-T cells displayed preferable proliferation. CAR-T cells sorted for CAR expression were incubated with LHL2/3 cells (5 × 105cells) at 1:1 ratio for 5 days, and CAR+cells were counted daily to evaluate thein vitro proliferation. Jiang, Zhengtao, et al. "HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo." Frontiers in Microbiology 12 (2021): 684016. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3BNC117-41BB-CD3ζ
Fig.3 Cell killing assay. Direct killing of LEL6 was performed using the LDH release assay. Jiang, Zhengtao, et al. "HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo." Frontiers in Microbiology 12 (2021): 684016. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3BNC117-41BB-CD3ζ
Fig.4 cytotoxicity assay. Direct cytotoxicity effects on Jurkat cells, as the Env negative control here, were detected Jiang, Zhengtao, et al. "HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo." Frontiers in Microbiology 12 (2021): 684016. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3BNC117-41BB-CD3ζ
Fig.5 TNF-α, IL-2 and IFN-γ production in co-cultures. Anti-HIV CAR-T cells were co-cultured with LEL6 cells (1 × 10^4cells) at 10:1 for 24 h, and supernatants were collected for ELISA. Jiang, Zhengtao, et al. "HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo." Frontiers in Microbiology 12 (2021): 684016. Distributed under Open Access license CC BY 4.0, without modification. |
|
CAR Construction : 3BNC117-41BB-CD3ζ
Fig.6 CAR-T cells eliminated LEL6 cells in vivo. CAR-T cells displayed superior anti-HIV function in an HIV NCG mouse model. Jiang, Zhengtao, et al. "HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo." Frontiers in Microbiology 12 (2021): 684016. Distributed under Open Access license CC BY 4.0, without modification. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-HIV-1 (3BNC117) h(CD3ζ) CAR, pCDCAR1 (CAR-MZ211). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
